Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Recruiting in Palo Alto (17 mi)

Overseen by Lisa Bodei, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

People with neuroendocrine cancer typically have imaging scans before and after treatment, including positron emission tomography (PET) scans. The scans are analyzed using a set of criteria that describes how the disease has responded to treatment. The purpose of this study is to establish new criteria for doctors to use when evaluating these PET scans. Researchers are testing whether these new criteria are useful for predicting whether a person's cancer gets better, gets worse, or stays the same. Researchers will also compare these new criteria to the current standard criteria for evaluating imaging scans.

Research Team

Lisa Bodei, MD, PhD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

Inclusion Criteria

My cancer can be measured by standard health scans.

My scans show high levels of certain receptors in my cancer spots compared to my liver.

My tumor is a certain type that shows up on special scans and cannot be removed by surgery.

Treatment Details

Participant Groups

Group I: People With Neuroendocrine Tumors having a PET/CT or MRI Experimental Treatment 1 Intervention

This is a non-interventional observational study of imaging.

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

Lisa M. DeAngelis

Memorial Sloan Kettering Cancer Center

Chief Medical Officer since 2021

MD from Columbia University

Selwyn M. Vickers

Memorial Sloan Kettering Cancer Center

Chief Executive Officer since 2022

MD from Johns Hopkins University

NeuroEndocrine Tumor Research Foundation (NETRF)

Collaborator

Trials

2

Recruited

60+